



NEWS RELEASE

For Further Information Contact:

Roy Wolvin
Nymox Pharmaceutical Corporation
1-800-93NYMOX
www.nymox.com

For Immediate Release:

Nymox Reports Third Quarter 2008 Financial Results

HASBROUCK HEIGHTS, NJ (November 14, 2008) Nymox Pharmaceutical Corporation (NASDAQ: NYMX) announced today its financial results for the third quarter of 2008. Nymox reported a net loss of \$1,350,536, or \$0.05 per share for the quarter ending September 30, 2008, compared to \$1,386,084, or \$0.05 per share for same period in 2007. Product sales amounted to \$82,171 for the third quarter of 2008, compared to \$62,132 for the same period in 2007. The weighted average number of common shares for the quarter ended September 30, 2008 was 29,815,670, compared to 29,646,249 for the same period in 2007.

Nymox Pharmaceutical Corporation is a biotechnology company engaged in the research and development of therapeutics and diagnostics, with a particular emphasis on products targeted for the unmet needs of the aging population. Currently Nymox has three products on the market, and a healthy pipeline of drug and diagnostic products. The Company also has several hundred patents and patent applications. The Company is in late stage development of NX-1207, a drug for benign prostatic hyperplasia (BPH). Nymox has a number of drugs in development for E. coli infection, Alzheimer's disease, oncology, and infectious disease. The Company offers NicAlert™ and TobacAlert™ tests for measuring tobacco product exposure, and AlzheimerAlert™, a test to aid in the diagnosis of Alzheimer's disease.

More information about Nymox is available at www.nymox.com, email: info@nymox.com, or 800-936-9669.

This press release contains certain "forward-looking statements" as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities.

###